Current and novel treatment options for actinic keratosis.

Overview

Actinic keratosis (AK), located on sun-exposed areas of the skin, is an increasing global health burden. Multiple ablative and topical treatment options are available to manage this disease; however, topical treatment options are receiving significant interest because AK is commonly associated with areas of substantial photodamage, and destructive modalities cannot effectively treat subclinical AK. Several topical therapies, including 0.5% and other 5-fluorouracil concentrations, photodynamic therapy, 3% diclofenac sodium gel, and imiquimod 5% cream, are indicated in the treatment of AK. This article will review key data on the efficacy and safety of several topical therapies in the treatment and management of AK. The review includes discussions of imiquimod 5% cream, approved in 2004 in the treatment of AK of the face or scalp. Whether administered as monotherapy or adjunctive therapy, topical therapies provide the opportunity to effectively manage AK and will likely emerge as an important tool for healthcare providers.